.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 9,155,717

« Back to Dashboard

Details for Patent: 9,155,717

Title:Pharmaceutical formulation containing irritant
Abstract: Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse; and an effective amount of an irritant to impart an irritating sensation to an abuser upon administration of said dosage form after tampering.
Inventor(s): Sackler; Richard (Greenwich, CT)
Assignee: Purdue Pharma L. P. (Stamford, CT)
Filing Date:Jan 07, 2014
Application Number:14/148,909
Claims:1. An oral dosage form consisting of: a therapeutically effective amount of a drug susceptible to abuse; a plurality of particles collectively consisting of said therapeutically effective amount of said drug susceptible to abuse; an effective amount of an irritant to impart a burning sensation to an abuser upon inhalation or injection of said dosage form after crushing, shearing, grinding, chewing, dissolution in a solvent, heating, or any combination thereof, and one or more additional pharmaceutical excipients; and a capsule containing said plurality of particles; wherein the particles are from about 0.1 mm to about 2.5 mm in diameter, and one of the additional pharmaceutical excipients is a sustained release carrier selected from the group consisting of gums, cellulose ethers, acrylic resins, protein derived materials, waxes, shellac, oils and mixtures of any of the foregoing materials.

2. The oral dosage form of claim 1, wherein the irritant is selected from the group consisting of capsaicin, a capsaicin analog, and mixtures thereof.

3. The oral dosage form of claim 1, wherein the irritant is a capsaicin analog selected from the group consisting of resiniferatoxin, tinyatoxin, heptanoylisobutylamide, heptanoyl guaiacylamide, other isobutylamides or guaiacylamides, dihydrocapsaicin, homovanillyl octylester, nonanoyl vanillylamide, and mixtures thereof.

4. The oral dosage form of claim 1, wherein the irritant is capsaicin.

5. The oral dosage form of claim 1, wherein the irritant is vanillylamide.

6. The oral dosage form of claim 1, wherein the irritant is in a sequestered form.

7. The oral dosage form of claim 1, wherein said drug is an opioid analgesic.

8. The oral dosage form of claim 7, wherein said opioid analgesic is morphine, codeine, tramadol, or a pharmaceutically acceptable salt of any of the foregoing.

9. The oral dosage form of claim 7, wherein said opioid analgesic is hydromorphone or a pharmaceutically acceptable salt thereof.

10. The oral dosage form of claim 7, wherein said opioid analgesic is hydrocodone or a pharmaceutically acceptable salt thereof.

11. The oral dosage form of claim 7, wherein said opioid analgesic is oxycodone or a pharmaceutically acceptable salt thereof.

12. The oral dosage form of claim 1, wherein said drug is selected from the group consisting of a tranquilizer, a CNS depressant, a CNS stimulant, a sedative hypnotic, or combinations thereof.

13. The oral dosage form of claim 1, wherein said burning sensation is provided after said inhalation of said dosage form after said crushing, shearing, grinding, or chewing.

14. The oral dosage form of claim 1, wherein the irritant is in an amount of about 0.00125% to about 50% by weight of the dosage form.

15. The oral dosage form of claim 1, wherein the irritant is in an amount of about 1 to about 7.5% by weight of the dosage form.

16. The oral dosage form of claim 1, wherein the irritant is in an amount of about 1 to about 5% by weight of the dosage form.

17. The oral dosage form of claim 11, wherein said opioid analgesic is oxycodone hydrochloride.

18. The oral dosage form of claim 1, wherein said burning sensation is provided after said inhalation of said dosage form after said crushing, shearing, grinding, chewing, dissolution in a solvent, heating, or any combination thereof.

19. The oral dosage form of claim 17, wherein oxycodone hydrochloride is in amount of from about 2.5 to about 320 mg.

20. The oral dosage form of claim 19, wherein oxycodone hydrochloride is in amount of 10 mg, 20 mg, 40 mg, or 80 mg.

21. The oral dosage form of claim 1, wherein one of the additional pharmaceutical excipients is a surfactant.

22. The oral dosage form of claim 1, wherein one of the additional pharmaceutical excipients is a fatty acid.

23. An oral dosage form consisting of a therapeutically effective amount of oxycodone or a salt thereof; a plurality of particles collectively consisting of: said therapeutically effective amount of said oxycodone or salt thereof; a sustained release carrier selected from the group consisting of gums, cellulose ethers, acrylic resins, protein derived materials, waxes, shellac, oils and mixtures of any of the foregoing materials, at least one aversive agent in an effective amount to discourage an abuser from tampering with the dosage form and thereafter inhaling, injecting, or swallowing the tampered dosage form, and additional pharmaceutical excipient(s); and a capsule containing said plurality of particles; wherein the particles are from about 0.1 to about 2.5 mm in diameter.

24. The oral dosage form of claim 23, wherein the aversive agent is capsaicin.

25. The oral dosage form of claim 24, wherein capsaicin is in an effective amount to impart a burning sensation to an abuser upon inhalation or injection of said dosage form after crushing, shearing, grinding, chewing, dissolution in a solvent, heating, or any combination thereof.

26. The oral dosage form of claim 23, wherein oxycodone hydrochloride is in amount of from about 2.5 to about 320 mg.

27. The oral dosage form of claim 23, wherein the particles have diameter of from about 0.2 mm to about 2 mm.

28. An oral dosage form consisting of a therapeutically effective amount of oxycodone or a salt thereof a plurality of particles collectively consisting of: said therapeutically effective amount of said oxycodone or salt thereof; a sustained release carrier selected from the group consisting of gums, cellulose ethers, acrylic resins, protein derived materials, waxes, shellac, oils and mixtures of any of the foregoing materials, and an aversive agent; and a capsule containing said plurality of particles; wherein the aversive agent is in an effective amount to discourage an abuser from tampering with the dosage form and thereafter injecting the tampered dosage form, and the particles are from about 0.1 to about 2.5 mm in diameter.

29. The oral dosage form of claim 28, wherein the aversive agent is capsaicin.

30. The oral dosage form of claim 29, wherein capsaicin is in an effective amount to impart a burning sensation to an abuser upon injection of said dosage form after crushing, shearing, grinding, chewing, dissolution in a solvent, heating, or any combination thereof.

31. The oral dosage form of claim 28, wherein oxycodone hydrochloride is in amount of from about 2.5 to about 320 mg.

32. The oral dosage form of claim 28, wherein the particles have diameter of from about 0.2 mm to about 2 mm.

33. The oral dosage form of claim 28, wherein the aversive agent is a surfactant.

34. The oral dosage form of claim 28, wherein the aversive agent is a fatty acid.

35. The oral dosage form of claim 23, wherein one of the additional pharmaceutical excipients is a surfactant.

36. The oral dosage form of claim 23, wherein one of the additional pharmaceutical excipients is a fatty acid.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc